🇺🇸 dextropropoxyphene hydrochloride in United States

159 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 159

Most-reported reactions

1. Condition Aggravated — 22 reports (13.84%)
2. Nausea — 18 reports (11.32%)
3. Dyspnoea — 17 reports (10.69%)
4. Renal Failure — 16 reports (10.06%)
5. Asthenia — 15 reports (9.43%)
6. Pain — 15 reports (9.43%)
7. Dizziness — 14 reports (8.81%)
8. Drug Interaction — 14 reports (8.81%)
9. Headache — 14 reports (8.81%)
10. Pyrexia — 14 reports (8.81%)

Source database →

Frequently asked questions

Is dextropropoxyphene hydrochloride approved in United States?

dextropropoxyphene hydrochloride does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for dextropropoxyphene hydrochloride in United States?

University Hospitals Bristol and Weston NHS Foundation Trust is the originator. The local marketing authorisation holder may differ — check the official source linked above.